FIELD: medicine.
SUBSTANCE: invention relates to medicine. Disclosed is use of biomarkers for evaluating the risk of developing infectious mononucleosis associated with Epstein-Barr virus, where biomarkers are genes BCL2L2, BCL2L11, CASP3, CASP7, CASP8, MAP3K14, MCL1, NFKB1 and mRNA BCL2-NM_000633, BCL2L1-NM_138578, BIRC2-NM_001166, TNFRSF10D-NM_003840, TRAF2-NM_021138, RELB-NM_006509, XIAP-NM_001167.
EFFECT: invention provides an effective assessment of the risk of developing complications of infectious mononucleosis associated with Epstein-Barr virus.
1 cl, 5 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DIAGNOSTIC TECHNIQUE FOR SEVERE FORM OF THE EBV-ASSOCIATED INFECTIOUS MONONUCLEOSIS | 2020 |
|
RU2732012C1 |
| METHOD FOR IDENTIFYING INFECTIOUS MONONUCLEOSIS ASSOCIATED WITH EPSTEIN-BARR VIRUS | 2019 |
|
RU2732813C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF INFECTIOUS MONONUCLEOSIS OF VARIOUS AETIOLOGY | 2019 |
|
RU2707077C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF HERPES VIRUS MIXED INFECTION | 2020 |
|
RU2739854C1 |
| METHOD FOR PREDICTION OF THE RISK OF DEVELOPING WEB-ASSOCIATED TUMORS IN THE PATIENTS WITH ACUTE EBV-INFECTION | 2019 |
|
RU2707075C1 |
| METHOD FOR PREDICTION OF SEVERITY OF EBV-ASSOCIATED INFECTIOUS MONONUCLEOSIS | 2020 |
|
RU2732010C1 |
| METHOD FOR DETECTION OF GENOTYPES 1 AND 2 OF EPSTEIN-BARR VIRUS | 2022 |
|
RU2789353C1 |
| METHOD FOR IDENTIFYING INFECTIOUS MONONUCLEOSIS ASSOCIATED WITH TYPE 6 HUMAN HERPES VIRUS | 2019 |
|
RU2729413C1 |
| METHOD FOR SIMULTANEOUS DETECTION OF LYMPHOTROPIC HERPESVIRUSES HHV6A, HHV6B, EBV AND ITS MAIN GENOTYPES EBV-1 AND EBV-2 | 2023 |
|
RU2805956C1 |
| METHOD OF DIFFERENTIAL EXPRESS DIAGNOSTICS OF ACUTE VIRAL AND BACTERIAL INFECTIONS | 2015 |
|
RU2602677C1 |
